Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin vs Rewetting Drops for Contact Lens-Related Dry Eye
NCT01105624Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of AzaSite in Contact lens-associated dry eye (CLADE) (2 arms), sponsored by Merck & Co. Primary endpoint: Subject-reported comfortable contact lens daily wear time at 4 weeks. Started Mar 2010; status: completed.
02
Drugs
AzaSite
03
Conditions
Contact lens-associated dry eye (CLADE)
Beyond the preview
Go deeper on NCT01105624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01105624.